Lumateperone safety study for children with schizophrenia, bipolar, or autism
Treatments studied
Part of Mental health clinical trials.
This trial tests a medication called lumateperone for children and teens with schizophrenia, bipolar disorder, or autism spectrum disorder. It aims to see if the medicine is safe and tolerable over time.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child must be between 5 and 17 years old, depending on their diagnosis: schizophrenia (13–17), bipolar I or II (10–17), or autism (5–17).
- They must have a confirmed diagnosis of schizophrenia, bipolar I or II, or autism spectrum disorder.
- They should be living at home (not in a hospital) and stay outpatient for the study.
- They cannot have a different major psychiatric disorder, but ADHD with stable medication is allowed, and mild to moderate intellectual disability is okay for children with autism.
- They must not have had recent suicidal thoughts or attempts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is testing how safe and tolerable an investigational medication is over the long term (52 weeks) when added to your current antipsychotic treatment. It's for people with schizophrenia whose symptoms are stable, and it aims to see if the new medication can help without causing serious side effects.
This trial tests a medication called lumateperone to see if it can improve apathy (lack of motivation) in people who have psychotic symptoms from schizophrenia or related disorders. It may help if you are already on a stable treatment but still struggle with apathy.
This trial tests whether adding lumateperone, an antipsychotic medication, to clozapine can improve metabolic health in people with schizophrenia. It aims to see if this combination helps with weight, blood sugar, and cholesterol levels.
This trial tests an oral liquid medicine (called NTI164) to see if it helps reduce symptoms of autism in children and teens. It may be an option if current treatments haven't fully helped, but it requires regular study visits and certain health rules.
This Phase 4 study checks how safe and well-tolerated iloperidone is when used in a typical, open-label way for teenagers. It may help doctors better understand side effects and safety in teens with schizophrenia or bipolar I disorder.
This study tests a combination medicine (xanomeline and trospium chloride) to see if it is safe and tolerable over a longer period for children and adolescents with psychiatric disorders, especially those with autism-related irritability. It may help families understand if this treatment can be used beyond the initial study period.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.